ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Attovia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$13.89+0.16 (+1.17%)
Close on Oct 19, 2026
- Market cap
- $58.86M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$13.42 (+2,855%)past year
Weekly closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $58.86M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- -$34.33
- Diluted shares
- 4M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period